Preparing for Your First EU GMP Inspection

Executive Summary

A first EU GMP inspection is one of the most significant events in a cannabis manufacturer's compliance journey. The outcome determines whether the facility can operate as a licensed GMP manufacturer — and the preparation invested in the months beforehand largely determines the outcome.

This white paper provides a practical guide to inspection preparation, covering what inspectors look for, how to organise your team and documentation, what the most common findings are and how to avoid them.

1. What EU GMP Inspections Assess

EU GMP inspections are conducted by national competent authorities under the mandate of Directive 2001/83/EC and the associated GMP guidelines in EudraLex Volume 4. The inspection scope covers the entire quality management system, not just documentation or facilities.

Inspectors assess whether the quality system is implemented in practice, not just written down. The key question at every stage of inspection is not "does a procedure exist?" but "does actual practice match the procedure, and is there evidence?"

For pharmaceutical cannabis manufacturers, inspection scope typically includes:

• Quality Management System — structure, document control, CAPA, change control, management review
• Personnel — organisation, training, qualification, hygiene
• Premises and equipment — facility design, qualification status, maintenance, cleaning
• Documentation — batch records, SOPs, specifications, validation protocols and reports
• Production — manufacturing process, in-process controls, batch traceability
• Quality Control — testing, out-of-specification investigations, stability
• Outsourced activities — contract manufacturers, contract testing laboratories, GACP suppliers
• Complaints and recalls — system design and any live cases
• Self-inspections — programme and findings

2. The Inspection Timeline

Pre-inspection notification

Routine GMP inspections are typically notified 4–8 weeks in advance. For initial inspections prior to GMP certification, the timeframe may be longer. The notification letter will specify the scope, the inspection team and the documents requested in advance — typically including the Site Master File, Validation Master Plan and recent batch records.

Opening meeting

The inspection begins with an opening meeting attended by senior management, QA and technical leads. Inspectors will outline the scope and programme. The facility will typically present a brief overview of operations. This is not the time for lengthy presentations — inspectors want to begin the substantive inspection as quickly as possible.

Facility tour

Inspectors will walk through the manufacturing facility, paying particular attention to gowning procedures, material flows, classified zone conditions and actual practice relative to documented procedures. Anything visible during the tour may trigger a documentation request or a deviation finding.

Documentation review

The bulk of most inspections involves document review. Inspectors will select batch records, SOPs, deviation records, CAPA records, training records and qualification documentation for detailed review. Selection is not random — inspectors will typically follow the trail from any finding identified during the facility tour.

Closing meeting

Inspectors summarise preliminary findings, categorised as critical, major or other (minor). The facility has the opportunity to provide immediate clarification. Written findings follow within a defined timeframe, and the facility must provide a formal CAPA response.

3. Document Readiness

The following documents should be current, approved, implemented and retrievable before inspection:

Document	Status required	Common gap
Site Master File	Current, approved, reflecting actual operations	Out of date; does not reflect current product portfolio or facility layout
Validation Master Plan	Current; all referenced validation activities completed or on approved timeline	Validation activities listed as planned but not yet executed
Contamination Control Strategy	Formally approved; Annex 1 (2022) compliant	Absent; or present but not risk-based or cannabis-specific
EMPQ Report	Complete; limits formally approved	Limits set by reference to grade limits, not EMPQ baseline
Cleaning Validation Reports	Complete for all shared equipment; PDE-based limits	Arbitrary 10 ppm limits; recovery not corrected for swab efficiency
Training Records	Complete; role-specific; current for all personnel with GMP access	Gaps in training records for specific individuals; training not competency-assessed
Deviation Records	All deviations documented; investigations complete; CAPA closed and effective	Deviations not raised; investigations superficial; CAPA not verified as effective

4. The Ten Most Common Inspection Findings in Cannabis Manufacturing

1. Contamination Control Strategy absent or inadequate — the most frequently cited finding in post-2022 inspections of cannabis facilities. Annex 1 (2022) requires a formal, risk-based CCS. Many facilities have not produced one.
2. Environmental monitoring limits not justified — alert and action limits set by reference to grade limits rather than EMPQ baseline data.
3. Cleaning validation limits not health-based — arbitrary limits used rather than PDE-derived acceptance criteria.
4. GACP supplier qualification inadequate — no formal qualification, no quality agreement, no incoming testing programme adequate to demonstrate material identity, quality and freedom from contamination.
5. Training records incomplete — missing records for specific personnel; training delivered but not assessed for competency.
6. Deviations not raised — actual practice deviating from procedure but no deviation recorded; out-of-specification results investigated inadequately.
7. Change control not implemented — changes to process, equipment or facility made without formal change control; retrospective documentation of changes.
8. Data integrity gaps — audit trails not enabled or not reviewed; data deletions not justified; access control inadequate.
9. Site Master File not current — SMF does not reflect current operations, product portfolio or facility description.
10. Self-inspection programme absent or ineffective — no internal audit programme; or audits conducted but findings not addressed.

5. Inspection Day Conduct

The quality of inspection day conduct significantly affects inspection outcome. Key principles:

• Answer the question asked. Do not volunteer additional information. Do not guess. If you do not know, say so and undertake to provide the information.
• Escalate requests appropriately. All requests from inspectors should be managed through a designated inspection coordinator who logs the request, obtains the document or answer, and responds. Inspectors should not be left waiting.
• Do not dispute findings during the inspection. If a finding is incorrect, provide clarification respectfully and with supporting evidence. Lengthy arguments during the inspection are counterproductive.
• Maintain a contemporaneous log. Record every inspector request, every document provided and every verbal comment. This becomes the basis for the CAPA response.

6. Post-Inspection CAPA Response

The written CAPA response to inspection findings is as important as the inspection itself. A weak CAPA response — proposing superficial corrective actions, failing to address root cause, or setting unrealistic timelines — will extend the inspection cycle and damage the relationship with the authority.

Each finding requires: acknowledgement; root cause analysis; immediate corrective action; preventive action to prevent recurrence; evidence that the action has been implemented; and proposed verification method and timeline.

7. References

• European Commission. EudraLex Volume 4 — EU GMP Guidelines. Parts I, II and Annexes.
• EU GMP Annex 1 (2022) — Manufacture of Sterile Medicinal Products.
• EMA. Compilation of Community Procedures on Inspections and Exchange of Information.
• PIC/S. Guide to Good Manufacturing Practice for Medicinal Products (PE 009-16).
• ICH Q9(R1) — Quality Risk Management.
• EMA. Reflection Paper on GMP for Advanced Therapy Medicinal Products. (Referenced for approach to novel product types.)